Ipi 10 was not approved as an adjuvant therapy in Europe due to its association with a relatively high rate of trAEs, and the emergence of PD-1-inhibiting antibodies as a more efficacious and better tolerated adjuvant therapy for stage III melanoma patients [52]. This evidence concerns the gene PDCD1 and melanoma.